Oncology:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      UK-VNCAML-220206. Date of Preparation: November 2022.

      ASH 2022 - The 64th American Society of Haematology Annual Meeting and Exposition

      FIND OUT MORE

      About the latest data for VENCLYXTO® in Acute Myloid Leukaemia (AML)

      SIGN UP NOW

      To receive the latest AbbVie information on upcoming congresses

      On demand: Access content from ASH 2022

      Dr Priyanka Mehta

      Dr Mehta discusses the long-term follow-up of VIALE-A trial

      Professor Charlie Craddock

      Professor Craddock discusses ELN risk stratification and outcomes with venetoclax and azacitidine

      VENCLYXTO AML PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on [email protected]

      UK-VNCAML-220255. Date of Preparation: February 2023.